ECOR
Price
$7.71Alerts
Change
-$0.01 (-0.13%)
Updated
Nov 11 closing price
Capitalization
65.37M
119 days until earnings call
Intraday BUY SELL Signals
HAE
Price
$120.63Alerts
Change
-$1.73 (-1.41%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
5.46B
91 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ECOR vs HAE

ECOR vs HAE Comparison Chart in %
View a ticker or compare two or three
VS
ECOR vs. HAE commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ECOR is a StrongBuy and HAE is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ECOR with price predictions
Nov 11, 2026

ECOR in +21.71% Uptrend, rising for three consecutive days on November 05, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ECOR advanced for three days, in 240 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ECOR's RSI Indicator exited the oversold zone, 17 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for ECOR just turned positive on November 04, 2026. Looking at past instances where ECOR's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ECOR as a result. In 79 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

ECOR moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ECOR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ECOR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

ECOR broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ECOR entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ECOR's P/B Ratio (-23.428) is slightly lower than the industry average of (4.142). P/E Ratio (-4.394) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.571) is also within normal values, averaging (40.124).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. ECOR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ECOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for HAE with price predictions
Nov 11, 2026

Aroon Indicator for HAE shows an upward move is likely

HAE's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 212 similar instances where the Aroon Indicator showed a similar pattern. In 162 of the 212 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on HAE as a result. In 53 of 70 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

Following a +6.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where HAE advanced for three days, in 233 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

Bearish Trend Analysis

The 10-day RSI Indicator for HAE moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 29 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.

The Moving Average Convergence Divergence Histogram (MACD) for HAE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 23 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HAE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

HAE broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HAE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.518) is normal, around the industry mean (4.142). P/E Ratio (57.659) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.676) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.668) is also within normal values, averaging (40.124).

FUNDAMENTALS RATINGS
ECOR vs HAE: Fundamental Ratings
ECOR
HAE
OUTLOOK RATING
1..100
914
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
88
Overvalued
PROFIT vs RISK RATING
1..100
10044
SMR RATING
1..100
10066
PRICE GROWTH RATING
1..100
6035
P/E GROWTH RATING
1..100
714
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ECOR's Valuation (18) in the Medical Specialties industry is significantly better than the same rating for HAE (88). This means that ECOR’s stock grew significantly faster than HAE’s over the last 12 months.

HAE's Profit vs Risk Rating (44) in the Medical Specialties industry is somewhat better than the same rating for ECOR (100). This means that HAE’s stock grew somewhat faster than ECOR’s over the last 12 months.

HAE's SMR Rating (66) in the Medical Specialties industry is somewhat better than the same rating for ECOR (100). This means that HAE’s stock grew somewhat faster than ECOR’s over the last 12 months.

HAE's Price Growth Rating (35) in the Medical Specialties industry is in the same range as ECOR (60). This means that HAE’s stock grew similarly to ECOR’s over the last 12 months.

HAE's P/E Growth Rating (4) in the Medical Specialties industry is significantly better than the same rating for ECOR (71). This means that HAE’s stock grew significantly faster than ECOR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ECORHAE
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
56%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
63%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
60%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 8 days ago
69%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
64%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
76%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ECOR: $7.72 vs. HAE: $122.36)
Brand notoriety: ECOR and HAE are both not notable
Both companies represent the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: ECOR: 97% vs. HAE: 111%
Market capitalization -- ECOR: $65.37M vs. HAE: $5.46B
ECOR [@Medical/Nursing Services] is valued at $65.37M. HAE’s [@Medical/Nursing Services] market capitalization is $5.46B. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ECOR’s FA Score shows that 1 FA rating(s) are green while HAE’s FA Score has 1 green FA rating(s).

  • ECOR’s FA Score: 1 green, 4 red.
  • HAE’s FA Score: 1 green, 4 red.
According to our system of comparison, HAE is a better buy in the long-term than ECOR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ECOR’s TA Score shows that 4 TA indicator(s) are bullish while HAE’s TA Score has 4 bullish TA indicator(s).

  • ECOR’s TA Score: 4 bullish, 6 bearish.
  • HAE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, HAE is a better buy in the short-term than ECOR.

Price Growth

ECOR (@Medical/Nursing Services) experienced а +6.78% price change this week, while HAE (@Medical/Nursing Services) price change was +1.73% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.

Reported Earning Dates

ECOR is expected to report earnings on Mar 11, 2027.

HAE is expected to report earnings on Feb 11, 2027.

Industries' Descriptions

@Medical/Nursing Services (-2.89% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ECOR and

Correlation & Price change

A.I.dvisor tells us that ECOR and SENS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ECOR and SENS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ECOR
1D Price
Change %
ECOR100%
-0.13%
SENS - ECOR
30%
Poorly correlated
+3.89%
QDEL - ECOR
29%
Poorly correlated
+3.39%
PFSA - ECOR
28%
Poorly correlated
+0.18%
AXGN - ECOR
26%
Poorly correlated
+15.21%
EW - ECOR
26%
Poorly correlated
+1.73%
More

HAE and

Correlation & Price change

A.I.dvisor indicates that over the last year, HAE has been loosely correlated with SRTS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HAE jumps, then SRTS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HAE
1D Price
Change %
HAE100%
-1.49%
SRTS - HAE
44%
Loosely correlated
+3.33%
ECOR - HAE
43%
Loosely correlated
-0.13%
PEN - HAE
42%
Loosely correlated
+0.08%
ATR - HAE
41%
Loosely correlated
-0.72%
GH - HAE
39%
Loosely correlated
-0.37%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ELCV31.160.32
+1.04%
Eventide High Dividend ETF (ELCV)
HDG53.820.29
+0.54%
ProShares Hedge Replication ETF (HDG)
SUSC22.260.02
+0.11%
iShares ESG Aware USD Corporate Bond ETF (SUSC)
GLBL27.97N/A
N/A
Pacer MSCI World Industry Advantage ETF
SHNY6.71-0.26
-3.73%
MicroSectors Gold 3X Leveraged ETNs (SHNY)